SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-168704
Filing Date
2021-05-21
Accepted
2021-05-21 09:30:30
Documents
5
Period of Report
2021-05-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d188842d8k.htm 8-K 30178
2 EX-4.1 d188842dex41.htm EX-4.1 104867
3 EX-10.1 d188842dex101.htm EX-10.1 165255
4 EX-10.2 d188842dex102.htm EX-10.2 85216
5 EX-10.3 d188842dex103.htm EX-10.3 109003
  Complete submission text file 0001193125-21-168704.txt   495874
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 21946823
SIC: 2834 Pharmaceutical Preparations